Allena Pharmaceuticals, Inc. Capital Expenditures

Capital Expenditures of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital Expenditures for the quarter ending December 31, 2021 was $-25 Thousand (a -86.49% decrease compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures decreased by -94.08%
  • Annual Capital Expenditures for 2021 was $-667 Thousand (a 5.54% increase from previous year)
  • Annual Capital Expenditures for 2020 was $-632 Thousand (a 418.03% increase from previous year)
  • Annual Capital Expenditures for 2019 was $-122 Thousand (a -61.64% decrease from previous year)
  • Twelve month Capital Expenditures ending December 31, 2021 was $-667 Thousand (a -47.65% decrease compared to previous quarter)
  • Twelve month trailing Capital Expenditures decreased by -37.95% year-over-year
Trailing Capital Expenditures for the last four month:
31 Dec '21 30 Sep '21 30 Jun '21 31 Mar '21
$-667 Thousand $-1.27 Million $-1.09 Million $-1.08 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of Allena Pharmaceuticals, Inc.

Most recent Capital Expendituresof ALNA including historical data for past 10 years.

Interactive Chart of Capital Expenditures of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.03 $-0.19 $-0.04 $-0.42 $-0.67
2020 $-0.63 $-0.63
2019 $0.0 $-0.02 $-0.02 $-0.08 $-0.12
2018 $-0.16 $-0.04 $-0.08 $-0.03 $-0.32
2017 $-0.0 $0.0 $-0.01 $-0.05 $-0.06
2016 $-0.05 $-0.05 $-0.1
2015 $0.01 $0.01

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.